Related Experiment Videos
[Drugs active against retroviruses]
1Laboratoire de virologie, Hôpital Bichat-Claude-Bernard, Paris.
La Revue Du Praticien
|March 15, 1997
Summary
Recent advances in human immunodeficiency virus (HIV) treatment include nucleoside analogues and protease inhibitors targeting viral enzymes. This review covers their mechanisms, resistance, and emerging drug development for HIV therapy.
Area of Science:
- Virology
- Pharmacology
- Infectious Diseases
Context:
- Human Immunodeficiency Virus (HIV) infection remains a significant global health challenge.
- Antiretroviral therapy (ART) has evolved significantly, improving patient outcomes.
- Understanding viral pathogenesis is crucial for developing effective treatments.
Purpose:
- To review the mechanisms of action for current antiretroviral drugs targeting HIV.
- To discuss patterns of drug resistance associated with HIV therapy.
- To highlight emerging compounds in HIV treatment development.
Summary:
- Current HIV treatment primarily targets viral reverse transcriptase and protease enzymes.
- Nucleoside analogues were the initial class of effective antiretroviral drugs.
- Protease inhibitors represent a newer therapeutic approach, showing promise in combination therapy.
- This review details the efficacy and resistance profiles of these key drug classes.
Impact:
- Provides a comprehensive overview of established and novel HIV therapeutic strategies.
- Informs clinicians and researchers about current treatment options and future directions.
- Contributes to the ongoing effort to combat the HIV/AIDS pandemic through optimized drug therapies.